2-[[4-[[(2-amino-4-oxo-3H-pteridin-6-yl)amino]methyl]benzoyl]amino]-5-(3-methylbutylamino)-5-oxopentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[4-[[(2-amino-4-oxo-3H-pteridin-6-yl)amino]methyl]benzoyl]amino]-5-(3-methylbutylamino)-5-oxopentanoic acid
• 化学式: C₂₄H₃₀N₈O₅
• 分子量: 510.5
• InChiKey: BAXVKTAKSKQSBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  201
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• [EN] TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF<br/>[FR] CONJUGUÉS CIBLÉS ENCAPSULÉS DANS DES PARTICULES ET FORMULATIONS CORRESPONDANTES
  申请人：BLEND THERAPEUTICS INC

  公开号：WO2014106208A1

  公开（公告）日：2014-07-03

  Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.